Skip to main content
. Author manuscript; available in PMC: 2021 Aug 14.
Published in final edited form as: Mol Cancer Ther. 2020 Sep 2;19(11):2319–2329. doi: 10.1158/1535-7163.MCT-20-0101

Figure 3: mTOR inhibition improves survival after combined treatment with EGFR and menin inhibitors.

Figure 3:

A/B) HT-29 cells were pre-treated with vehicle, 1 μM MI-2–2, and/or 1 μM everolimus for 24 hours, followed by assessment of glucose consumption (A) and lactate production (B) over an 8-hour period after treatment with vehicle or 10 μM gefitinib. C) Treatment of HT-29 cells with cell growth assessed after 96 hours by MTS assay, 10 μM gefitinib, 1 μM MI-2–2, 1 μM everolimus. D) Treatment of HT-29 cells for 48 hours, 10 μM gefitinib, 1 μM MI-2–2, 1 μM everolimus. E) Treatment of HT-29 cells with cell growth assessed after 96 hours by MTS assay, 10 μM gefitinib, 1 μM MI-2–2, 1 μM rapamycin. F) Treatment of HT-29 cells for 48 hours, 10 μM gefitinib, 1 μM MI-2–2, 1 μM everolimus. * p < 0.05.